In recent years, with the further understanding of the pathogenesis of pulmonaryarterial hypertension, great progress in the diagnosis and treatment of pulmonary arterial hypertension has been made. The use of targeted drugs to a certain extent improves the illness development of patients with pulmonary arterial hypertension, but the long-term prognosis of the disease is still not optimistic. Therefore, seeking reliable biomarkers which can monitor disease severity, prognosis and the response to treatment in patients seems crucial. There are a number of researches at home and abroad looking for non-invasive biomarkers which can objectively evaluate theseverity and prognosis of the disease. In this paper part of the biomarkers are briefly reviewed.